Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats
- PMID: 3584483
- PMCID: PMC1140972
- DOI: 10.1136/jcp.40.4.404
Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats
Abstract
A novel iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, and desferrioxamine were compared for their ability to remove iron and for their site of action in iron release in rats. Repeated intraperitoneal injections of the chelators in rats with widespread tissue labelling by 59Fe derived from transferrin showed comparable 59Fe mobilisation by each chelator in normal and iron loaded rats. Specific labelling of a chelatable "cold" iron pool in hepatocytes by 59Fe derived from ferritin showed this pool to be equally accessible to parenteral doses of both chelators and also to oral 1,2-dimethyl-3-hydroxypyrid-4-one, which is an effective oral iron chelating agent that removes iron from parenchymal cells. This and other alpha-ketohydroxypyridines need further development as potential therapeutic agents in human iron overload.
Similar articles
-
Effect of novel 1-alkyl-3-hydroxy-2-methylpyrid-4-one chelators on uptake and release of iron from macrophages.Am J Hematol. 1990 May;34(1):21-5. doi: 10.1002/ajh.2830340106. Am J Hematol. 1990. PMID: 2327400
-
Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.Am J Hematol. 1993 Apr;42(4):340-9. doi: 10.1002/ajh.2830420403. Am J Hematol. 1993. PMID: 8493983
-
Hepatocyte iron kinetics in the rat explored with an iron chelator.Br J Haematol. 1982 Oct;52(2):211-24. doi: 10.1111/j.1365-2141.1982.tb03883.x. Br J Haematol. 1982. PMID: 7126464
-
Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs.Toxicol Lett. 1995 Oct;80(1-3):1-18. doi: 10.1016/0378-4274(95)03415-h. Toxicol Lett. 1995. PMID: 7482575 Review.
-
Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.Hemoglobin. 2006;30(2):183-200. doi: 10.1080/03630260600642450. Hemoglobin. 2006. PMID: 16798643 Review.
Cited by
-
Iron chelating drugs.Br Med J (Clin Res Ed). 1988 Jun 11;296(6637):1672-3. doi: 10.1136/bmj.296.6637.1672-c. Br Med J (Clin Res Ed). 1988. PMID: 3135073 Free PMC article. No abstract available.
-
Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP94.Biometals. 1994 Oct;7(4):267-71. doi: 10.1007/BF00144120. Biometals. 1994. PMID: 7812111
-
Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.Indian J Pediatr. 1993 Jul-Aug;60(4):485-507. doi: 10.1007/BF02751425. Indian J Pediatr. 1993. PMID: 8262586 Review.
-
In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.Pharm Res. 1999 Mar;16(3):434-40. doi: 10.1023/a:1018886005136. Pharm Res. 1999. PMID: 10213376
-
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970. Int J Mol Sci. 2023. PMID: 36902402 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources